Leerink Partnrs Brokers Cut Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) – Research analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for United Therapeutics in a research report issued to clients and investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings per share of $25.91 for the year, down from their previous forecast of $25.95. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for United Therapeutics’ current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics’ Q4 2024 earnings at $6.67 EPS and FY2025 earnings at $26.98 EPS.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $0.08. The company had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a return on equity of 17.72% and a net margin of 42.31%. The firm’s quarterly revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the company earned $2.67 EPS.

Several other brokerages also recently issued reports on UTHR. Wells Fargo & Company lifted their target price on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research note on Thursday, March 7th. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price for the company. The Goldman Sachs Group upgraded United Therapeutics from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $292.67.

United Therapeutics Stock Up 0.4 %

Shares of UTHR opened at $237.93 on Friday. The business’s 50 day moving average is $231.71 and its 200 day moving average is $228.55. The company has a market capitalization of $11.20 billion, a PE ratio of 11.99 and a beta of 0.52. United Therapeutics has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05.

Institutional Trading of United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC purchased a new stake in shares of United Therapeutics during the first quarter valued at about $32,000. Atlas Capital Advisors LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of United Therapeutics by 49.6% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 65 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at about $43,000. Finally, Neo Ivy Capital Management purchased a new stake in shares of United Therapeutics during the second quarter valued at about $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $237.91, for a total value of $856,476.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,928.30. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Martine A. Rothblatt sold 13,800 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $237.27, for a total value of $3,274,326.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,845.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 3,600 shares of the company’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $237.91, for a total transaction of $856,476.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,928.30. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 129,790 shares of company stock worth $30,528,633. Insiders own 12.50% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.